Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to -$219.1 million.

  • Editas Medicine's Free Cash Flow rose 43.66% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.7 million, marking a year-over-year increase of 5.57%. This contributed to the annual value of -$219.1 million for FY2024, which is 60.05% down from last year.
  • Editas Medicine's Free Cash Flow amounted to -$219.1 million in FY2024, which was down 60.05% from -$136.9 million recorded in FY2023.
  • Over the past 5 years, Editas Medicine's Free Cash Flow peaked at -$136.9 million during FY2023, and registered a low of -$219.1 million during FY2024.
  • Its 3-year average for Free Cash Flow is -$179.2 million, with a median of -$181.5 million in 2022.
  • Per our database at Business Quant, Editas Medicine's Free Cash Flow crashed by 299.28% in 2020 and then grew by 24.56% in 2023.
  • Over the past 5 years, Editas Medicine's Free Cash Flow (Yearly) stood at -$187.0 million in 2020, then climbed by 8.14% to -$171.8 million in 2021, then declined by 5.64% to -$181.5 million in 2022, then increased by 24.56% to -$136.9 million in 2023, then plummeted by 60.05% to -$219.1 million in 2024.